NBIX — NEUROCRINE BIOSCIENCES INC

—
Nasdaq · Health Care · Biotechnology · CIK 914475 ·
Last close
$138.40
Market Cap
$14.07B
52W High
$186.12
52W Low
$122.14
ADV30
1,150,083
Next earnings
2026-10-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 959,000,000 935,800,000 153,000,000 144,400,000 5,359,100,000 332,400,000 1,665,500,000
Mar 2026 814,500,000 800,700,000 186,000,000 197,900,000 4,906,200,000 266,500,000 1,498,800,000
Dec 2025 805,500,000 787,900,000 227,900,000 153,700,000 4,631,500,000 713,000,000 1,378,400,000
Sep 2025 794,900,000 780,900,000 239,300,000 209,500,000 4,265,700,000 340,200,000 1,262,100,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$898,100,000
Investing CF
$-891,200,000
Financing CF
$60,200,000
CapEx
$-42,600,000
Dividends Paid
—
Buybacks
$-66,000,000
EPS Diluted TTM
$6.82
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$724,000,000
Inventory
$104,200,000
Receivables
$887,000,000
ST Investments
$57,400,000
EBIT TTM
$818,300,000
Pretax Income TTM
$940,200,000
Interest Exp TTM
$2,900,000
Analysts
27

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,373,900,032
EBITDA
$913,299,968
Free Cash Flow
$638,237,504
Enterprise Value
$15,951,434,752
Total Cash
$389,800,000
Total Debt
$461,600,000
Shares Out
101,649,181
Trailing EPS
$6.84
Book Value
$36.35
ROE
22.1%
ROA
11.7%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,860,500,000 636,500,000 478,600,000 4,631,500,000 1,378,400,000 3,253,100,000 782,700,000
Dec 2024 2,355,300,000 583,000,000 341,300,000 3,718,700,000 1,129,000,000 2,589,700,000 595,400,000
Dec 2023 1,887,100,000 394,800,000 249,700,000 3,251,400,000 1,019,400,000 2,232,000,000 389,900,000
Dec 2022 1,488,700,000 249,000,000 154,500,000 2,368,700,000 660,900,000 1,707,800,000 339,400,000

TTM Snapshot

Revenues TTM
$2,081,400,000
NetIncome TTM
$289,300,000
OpCashFlow TTM
$0
Assets (Latest)
$4,631,500,000
Forward EPS
$11.97

Max Pain — expiry 2026-12-18

max pain strike: $155.00 · spot: $137.11 · call oi: 1,745 · put oi: 3,277
Expected Move to 2026-12-18: ±$27.00 (19.69%) — implied range $110.11 – $164.11 · ATM straddle on $135.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
EXEL EXELIXIS, INC. $14.41B $58.16 —
HALO HALOZYME THERAPEUTICS, INC. $12.93B $113.90 —
TWST Twist Bioscience Corp $12.12B $182.83 —
TECH BIO-TECHNE Corp $11.39B $72.61 —
RGEN REPLIGEN CORP $10.70B $189.68 —

News headlines (Yahoo Finance, 1h cache)

Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
2026-09-23 04:02 · Yahoo
Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story
2026-09-18 04:47 · Yahoo
Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says
2026-09-08 15:50 · Yahoo
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
2026-09-02 20:01 · Yahoo
Neurocrine Biosciences (NBIX) Wins FDA Trial Nod, Is It Still Below Fair Value?
2026-08-28 02:18 · Yahoo
Neurocrine Biosciences (NBIX) Stock Looks Fairly Priced As 64% Gain Holds
2026-08-27 12:14 · Yahoo
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
2026-08-20 15:14 · Yahoo
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings
2026-08-12 23:42 · Yahoo
Neurocrine Biosciences shares fall amid Vykat safety concerns
2026-08-12 13:38 · Yahoo
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living wi
2026-08-12 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.